The LMN explains how the treatment is being used to manage or treat a diagnosed condition," says Pickner
Retatrutide is actually manufactured by Eli Lilly too, but has been dubbed a 'triple antagonist' as it activates three hormone receptors: GLP-1, GIP and glucagon receptor, to increase energy expenditure and potentially promote fat burning
Yes, with medical guidance
Khavinson VK, Myl'nikov SV
Most people on GLP-1s continue to enjoy food
Extending treatment to one year, the gap widens: about 4% greater weight loss in non-diabetics on semaglutide, and about 5.5% greater on tirzepatide. Some researchers suggest that behavioral differences such as motivation, adherence and engagement in lifestyle changes might help explain this gap